SWITCH SWEDEHEART Trial: Prasugrel Matches Ticagrelor with Less Bleeding

Prasugrel Policy Versus Ticagrelor in Real-World ACS Patients

A potent P2Y12 inhibitor combined with aspirin serves as the standard medical approach to prevent major cardiovascular events in patients with acute coronary syndromes who undergo percutaneous coronary intervention. However, the comparative effectiveness of prasugrel and ticagrelor in everyday clinical practice remained heavily debated prior to this trial, according to Principal Investigator Professor Elmir Omerovic from Sahlgrenska University Hospital in Gothenburg, Sweden.

While the earlier ISAR-REACT 5 trial indicated that a prasugrel-based strategy outperformed ticagrelor regarding major cardiovascular events without increasing major bleeding, researchers needed unselected population data. To solve this, seven Swedish healthcare regions adopted prasugrel as the default P2Y12 inhibitor for acute coronary syndrome patients. Investigators used this administrative transition to conduct a pragmatic evaluation through the established SWEDEHEART registry platform.

Stepped-Wedge Design and Trial Demographics

The SWITCH SWEDEHEART trial utilized a stepped-wedge design, randomizing entire geographic regions rather than individual patients. Seven Swedish regions spanning three clusters transitioned their default P2Y12 inhibitor policy from ticagrelor to prasugrel at staggered, randomly assigned intervals. This methodology captured 17,095 consecutive adult patients with acute coronary syndromes undergoing coronary stenting.

Crucially, the registry-based study included elderly patients, individuals with a history of prior stroke, and patients with active indications for oral anticoagulation—subgroups that conventional clinical trials frequently exclude. Under the prior ticagrelor policy, 9,444 patients received a recommendation for ticagrelor at 90 mg twice daily. Under the subsequent prasugrel policy, 7,651 patients received a recommendation for prasugrel at 10 mg once daily, with a reduced dose of 5 mg once daily for patients aged 75 years or older or those weighing under 60 kg, following the official drug label.

Cardiovascular Outcomes and Major Bleeding Rates at One Year

At the one-year mark, the primary endpoint—a composite of death from any cause, myocardial infarction, or stroke—occurred in nearly identical proportions between the two cohorts. Specifically, 11.1% of patients under the prasugrel policy experienced a primary endpoint event, compared with 11.8% of patients under the ticagrelor policy, yielding an adjusted odds ratio of 0.90 with a 95% confidence interval ranging from 0.77 to 1.06, as reported by European Society of Cardiology sources.

Individual components of the primary composite endpoint showed no statistically significant differences. However, the risk of major bleeding at one year was significantly lower among patients managed under the prasugrel policy compared to the ticagrelor policy. Major bleeding occurred in 4.2% of the prasugrel group versus 4.4% in the ticagrelor group, producing an odds ratio of 0.80 and a 95% confidence interval from 0.64 to 0.99.

One-Year Outcomes in the SWITCH SWEDEHEART Trial

Endpoint	Prasugrel Policy (7,651 patients)	Ticagrelor Policy (9,444 patients)	Adjusted Odds Ratio (95% CI)
Death, Myocardial Infarction, or Stroke	11.1%	11.8%	0.90 (0.77 to 1.06)
Major Bleeding	4.2%	4.4%	0.80 (0.64 to 0.99)

Implications for Healthcare Systems and Clinical Guidelines

The findings reinforce existing European cardiology recommendations. The 2023 ESC Guidelines already indicate that clinicians should consider prasugrel in preference to ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention, maintaining a class IIa, Level B recommendation. The SWITCH SWEDEHEART results provide robust, real-world randomized evidence supporting this position across a broad, unselected patient demographic.

Professor Omerovic highlighted both the clinical and economic value of the findings. “In the largest randomised comparison to date, prasugrel offered comparable protection against major cardiovascular events, but with a signal toward less bleeding and lower cost—a potentially important consideration for patients and healthcare systems,” he stated. Furthermore, the success of the trial’s registry infrastructure establishes a viable blueprint for future clinical research in cardiology and other medical specialties.

Frequently Asked Questions

What was the main finding of the SWITCH SWEDEHEART trial?

Prasugrel offered comparable protection against major cardiovascular events compared to ticagrelor in acute coronary syndrome patients after coronary stenting, but was associated with a significantly lower risk of major bleeding.

How many patients were included in the study?

The trial evaluated 17,095 consecutive adult patients across seven Swedish regions using a registry-based stepped-wedge randomized design.

How do the dosing regimens for prasugrel and ticagrelor differ in practice?

Ticagrelor is typically administered at 90 mg twice daily. Prasugrel is prescribed at 10 mg once daily, with a lowered dose of 5 mg once daily for patients aged 75 or older or those weighing less than 60 kg.

What are the current ESC guidelines regarding these two drugs?

The 2023 ESC Guidelines state that prasugrel should be considered in preference to ticagrelor for acute coronary syndrome patients who undergo percutaneous coronary intervention.

---

Join the Discussion: What are your clinical experiences with managing bleeding risks in patients undergoing percutaneous coronary intervention? Share your thoughts in the comments below, explore our related cardiology updates, or subscribe to our newsletter for the latest trial breakdowns straight from international congresses.